Dr. Mark Scholz, Executive Director of the PCRI, has generated an eight minute video discussing the major issues related to bone metastasis. Bone metastases generally occur in a small percentage of men and can appear 10-20 years after continuous prostate cancer treatment. Bone mets can be observed when the PSA levels exceed 20-30 or hundreds. The best method for detecting bone mets is the PSMA PET scan, if one can obtain access to it. Otherwise, standard bone and CT scans are used which also reveal enlarged lymph nodes. PSMA PET scans reveal metastases up to an 1/8th inch in width while other scans, 1/2 inch across. Bone mets indicate a potential life-threatening condition. Treatments include radiation and various hormone therapies. Fatigue can become a cumulative side effect. Exercise is very important. Bone metastases commonly spread to pelvic or back bone areas and can involve spinal chord compression. Xofigo is an approved drug for more than six metastatic sites; focused radiation can be used for fewer sites. Lutetium is a treatment not yet approved in the US but has been used overseas with some success. For the entire video, see the following link.
As I wrote this post, it hit home to me personally and seriously as I have advanced prostate cancer, with at least one metastatic site. However, my PSA remains very low and I am otherwise asymptomatic. Meanwhile, I am thanking my Lord and Savior Jesus Christ for his continual personal care, His Biblical promise of life eternal in a new heaven and a new earth with a new body and for the extraordinary physicians to which I have access. For additional help, see the following Scriptural Medicines.
Dr. Mark Scholz, Executive Director of the Prostate Cancer Research Institute (PCRI), has produced three very informative short videos dealing with topics such as 1) active surveillance (AS) for men recently diagnosed with prostate cancer, 2) bone metastasis and, 3) diet and cancer.
This first 7 minute AS video defines the terms “watchful waiting” as compared to “active surveillance”; cites the criteria for AS such as a Gleason 6 score, a PSA <10, and diagnostic procedures using MRI; discusses whether one can be sure of a Gleason 6 diagnosis; the utility of AS for long term care; monitoring of the cancer during AS utilizing periodic biopsies, PSA’s, and high quality MRI’s; signs to discontinue AS including increases in Gleason scores to >6; the use of PSA density; and, finally suggested diets. “Heart healthy diet is prostate healthy.” For the AS video, see the following link.
Using a comprehensive analysis of all the genetic risk data concerning prostate cancer for African American men, Dr. Chris Haiman of the University of Southern California and his team of over 200 researchers were able to determine that it was possible to create an affordable test, based solely on a man’s saliva or blood sample, to assess his risk of developing prostate cancer. The challenge now is to optimize the accuracy of this test and design a way to deliver it to all men.
The annual Prostate Cancer Research Institute (PCRI) Conference is a comprehensive educational experience for prostate cancer patients and caregivers. The conference moderated by Mark Moyad, MD, consists of keynote presentations from leading doctors followed by live question – and – answer sessions. Keynote topics include all treatments, newly-diagnosed, diet and exercise, sexual dysfunction, active surveillance, treatment side effects, prostate imaging and benign prostate hyperplasia (BPH). For the first time, this online event will be live-streamed free! You can attand from the comfort of your own home. You can expect to learn information that will empower you to make the best decisions. You can learn more about this unique educational event at www.pcri.org/2020-conference. To RSVP or subscribe see the following link. You may also contact PCRI at www.pcri.org/get-in-touch.